The premium of a big pharma license deal

Venture Valuation recently published an article in Nature Biotechnology 32, 617–619, (2014) based on data from its Biotechgate deals database looking at the difference between big pharma and SMEs in the upfront payments and number of deals. Read more here (Nature Biotechnology) To get access to Biotechgate, please contact us here.

The premium of a big pharma license deal

Source: Nature Biotechnology, 32, 617–619, (2014), doi:10.1038/nbt.2946, Published online 08 July 2014

Leave a Reply

Your email address will not be published. Required fields are marked *